CoChat
Sign Up
Cited by 689

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Tuberculosis

Frieden, Thomas R, Sterling, Timothy R, Munsiff, Sonal S, Watt, Catherine J, Dye, Christopher·2003·The Lancet
DOI 10.1016/s0140-6736(03)14333-4
Open this paper in CoChat — free account

Abstract

Among communicable diseases, tuberculosis is the second leading cause of death worldwide, killing nearly 2 million people each year. Most cases are in less-developed countries; over the past decade, tuberculosis incidence has increased in Africa, mainly as a result of the burden of HIV infection, and in the former Soviet Union, owing to socioeconomic change and decline of the health-care system. Definitive diagnosis of tuberculosis remains based on culture for Mycobacterium tuberculosis, but rapid diagnosis of infectious tuberculosis by simple sputum smear for acid-fast bacilli remains an important tool, and more rapid molecular techniques hold promise. Treatment with several drugs for 6 months or more can cure more than 95% of patients; direct observation of treatment, a component of the recommended five-element DOTS strategy, is judged to be the standard of care by most authorities, but currently only a third of cases worldwide are treated under this approach. Systematic monitoring of case detection and treatment outcomes is essential to effective service delivery. The proportion of patients diagnosed and treated effectively has increased greatly over the past decade but is still far short of global targets. Efforts to develop more effective tuberculosis vaccines are under way, but even if one is identified, more effective treatment systems are likely to be required for decades. Other modes of tuberculosis control, such as treatment of latent infection, have a potentially i…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(03)14333-4

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • All anti-TB drugs (isoniazid, rifampicin, pyrazinamide, ethambutol) have hepatotoxicity potential and could lead to DILI during anti-tuberculosis treatment, which commonly leads to interruption of anti-TB treatment and may promote antibiotic resistance.

    “All these anti-TB drugs have hepatotoxicity potential and could lead to DILI during M A N U S C R I P T ## A C C E P T E D ACCEPTED MANUSCRIPT anti-tuberculosis treatment, which commonly leads to interruption of anti-TB treatment and may promote antibiotic resistance.40”

    From Incidence and Etiology of Drug-Induced Liver Injury in Mainland China (2019) · cites this paper as [40]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 143

  1. Corbett, 2003, The growing burden of tuberculosis: global trends and interactions with the HIV epidemic, Arch Intern Med, 163, 1009, 10.1001/archinte.163.9.1009 · DOI · Paper page
  2. Shilova, 2001, The resurgence of tuberculosis in Russia, Philos Trans R Soc Lond Biol Sci, 356, 1069, 10.1098/rstb.2001.0895 · DOI
  3. Corbett, 2002, HIV-1/AIDS and the control of other infectious diseases in Africa, Lancet, 359, 2177, 10.1016/S0140-6736(02)09095-5 · DOI
  4. Wells, 1934, On air-borne infection: study II, droplets and droplet nuclei, Am J Hygiene, 20, 611
  5. Louden, 1966, Droplet expulsion from the respiratory tract, Am Rev Respir Dis, 95, 435
  6. Riley, 1959, Aerial dissemination of pulmonary tuberculosis: a two-year study of contagion in a tuberculosis ward, Am J Hygiene, 70, 185
  7. Comstock, 1974, The prognosis of a positive tuberculin reaction in childhood and adolescence, Am J Epidemiol, 99, 131, 10.1093/oxfordjournals.aje.a121593 · DOI
  8. Sutherland, 1976, Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli, Adv Tuberc Res, 19, 1
  9. Schluger, 1998, The host immune response to tuberculosis, Am J Respir Crit Care Med, 157, 679, 10.1164/ajrccm.157.3.9708002 · DOI
  10. Sodhi, 1997, Clinical correlates of interferon-gamma production in patients with tuberculosis, Clin Infect Dis, 25, 617, 10.1086/513769 · DOI
  11. Ellner, 1997, Review: The immune response in human tuberculosis: implications for tuberculosis control, J Infect Dis, 176, 1351, 10.1086/514132 · DOI
  12. Ting, 1999, Mycobacterium tuberculosis inhibits IFN-gamma transcriptional responses without inhibiting activation of STAT1, J Immunol, 163, 3898, 10.4049/jimmunol.163.7.3898 · DOI
  13. Flynn, 1993, An essential role for interferon-gamma in resistance to Mycobacterium tuberculosis infection, J Exp Med, 178, 2249, 10.1084/jem.178.6.2249 · DOI
  14. Flynn, 1995, Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice, Immunity, 2, 561, 10.1016/1074-7613(95)90001-2 · DOI
  15. Bean, 1999, Structural deficiencies in granuloma formation in TNF gene targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin, J Immunol, 162, 3504, 10.4049/jimmunol.162.6.3504 · DOI
  16. Flynn, 2000, Immune responses in tuberculosis, Curr Opin Immunol, 12, 432, 10.1016/S0952-7915(00)00116-3 · DOI
  17. American Thoracic Society, Centers for Disease Control and Prevention, 2000, Targeted tuberculin testing and treatment of latent tuberculosis infection, Am J Respir Crit Care Med, 161, S221, 10.1164/ajrccm.161.supplement_3.ats600 · DOI
  18. Wilkinson, 2000, Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study, Lancet, 355, 618, 10.1016/S0140-6736(99)02301-6 · DOI
  19. Karyadi, 2002, A double-blind, placebo-controlled study of vitamin A and zinc supplementation in persons with tuberculosis in Indonesia: effects on clinical response and nutritional status, Am J Clin Nutr, 75, 720, 10.1093/ajcn/75.4.720 · DOI
  20. Hirsch, 1999, Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy, J Infect Dis, 180, 2069, 10.1086/315114 · DOI
  21. Sterling, 2001, HIV-seronegative adults with extrapulmonary tuberculosis have abnormal innate immune responses, Clin Infect Dis, 33, 976, 10.1086/322670 · DOI
  22. Keane, 2001, Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent, N Engl J Med, 345, 1098, 10.1056/NEJMoa011110 · DOI
  23. Jouanguy, 1997, Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guerin infection and a sibling with clinical tuberculosis, J Clin Invest, 100, 2658, 10.1172/JCI119810 · DOI
  24. Altare, 2001, Interleukin-12 receptor beta1 deficiency in a patient with abdominal tuberculosis, J Infect Dis, 184, 231, 10.1086/321999 · DOI
  25. Comstock, 1978, Tuberculosis in twins: a re-analysis of the Prophit survey, Am Rev Respir Dis, 117, 621
  26. Stead, 1992, Genetics and resistance to tuberculosis, Ann Intern Med, 116, 937, 10.7326/0003-4819-116-11-937 · DOI
  27. Singh, 1983, Human leukocyte antigen (HLA)-linked control of susceptibility to pulmonary tuberculosis and association with HLA-DR types, J Infect Dis, 148, 676, 10.1093/infdis/148.4.676 · DOI
  28. Goldfeld, 1998, Association of an HLA-DQ allele with clinical tuberculosis, JAMA, 279, 226, 10.1001/jama.279.3.226 · DOI
  29. Bellamy, 1998, Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans, N Engl J Med, 338, 640, 10.1056/NEJM199803053381002 · DOI
  30. Greenwood, 2000, Linkage of tuberculosis to chromosome 2q35 loci, including NRAMP1, in a large aboriginal Canadian family, Am J Hum Genet, 67, 405, 10.1086/303012 · DOI
  31. Bellamy, 1999, Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene, J Infect Dis, 179, 721, 10.1086/314614 · DOI
  32. Delgado, 2002, Ethnic-specific genetic associations with pulmonary tuberculosis, J Infect Dis, 186, 1463, 10.1086/344891 · DOI
  33. Shafer, 1996, Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past decade, Clin Infect Dis, 22, 683, 10.1093/clinids/22.4.683 · DOI
  34. Rieder, 1990, Extrapulmonary tuberculosis in the United States, Am Rev Respir Dis, 141, 347, 10.1164/ajrccm/141.2.347 · DOI
  35. Roper, 1955, Primary serofibrinous pleural effusion in military personnel, Am Rev Tuberc, 71, 616
  36. Thwaites, 2000, Tuberculous meningitis, J Neurol Neurosurg Psychiatry, 68, 289, 10.1136/jnnp.68.3.289 · DOI
  37. Berenguer, 1992, Tuberculous meningitis in patients infected with the human immunodeficiency virus, N Engl J Med, 326, 668, 10.1056/NEJM199203053261004 · DOI
  38. American Thoracic Society, Centers for Disease Control and Prevention, 2000, Diagnostic standards and classification of tuberculosis in adults and children, Am J Respir Crit Care Med, 161, 1376, 10.1164/ajrccm.161.4.16141 · DOI
  39. Hesseling, 2002, A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis, Int J Tuberc Lung Dis, 6, 1038
  40. Shaw, 1954, Infectivity of pulmonary tuberculosis in relation to sputum status, Am Rev Tuberc, 69, 724
  41. Grzybowski, 1975, Contacts of cases of active pulmonary tuberculosis, Bull Int Union Tuberc, 50, 90
  42. Behr, 1999, Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli, Lancet, 353, 444, 10.1016/S0140-6736(98)03406-0 · DOI
  43. Crampin, 2001, Comparison of two versus three smears in identifying culture-positive tuberculosis patients in a rural African setting with high HIV prevalence, Int J Tuberc Lung Dis, 5, 994
  44. Morgan, 1983, Comparison study of a radiometric method (BACTEC) and conventional culture media for recovery of mycobacteria from smear-negative specimens, J Clin Microbiol, 18, 384, 10.1128/JCM.18.2.384-388.1983 · DOI
  45. Burman, 2000, Review of false-positive cultures for Mycobacterium tuberculosis and recommendations for avoiding unnecessary treatment, Clin Infect Dis, 31, 1390, 10.1086/317504 · DOI
  46. Nivin, 1998, Cross-contamination with Mycobacterium tuberculosis: an epidemiological and laboratory investigation, Infect Control Hosp Epidemiol, 19, 500, 10.2307/30141398 · DOI
  47. Woods, 2000, Susceptibility testing for mycobacteria, Clin Infect Dis, 31, 1209, 10.1086/317441 · DOI
  48. Cooksey, 1997, Evaluation of a line probe assay kit for characterization of rpoB mutations in rifampin-resistant Mycobacterium tuberculosis isolates from New York City, J Clin Microbiol, 35, 1281, 10.1128/JCM.35.5.1281-1283.1997 · DOI
  49. Jacobs, 1993, Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis by means of luciferase reporter phages, Science, 260, 819, 10.1126/science.8484123 · DOI
  50. Piatek, 1998, Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis, Nat Biotechnol, 16, 359, 10.1038/nbt0498-359 · DOI
  51. Piatek, 2000, Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing, Antimicrob Agents Chemother, 44, 103, 10.1128/AAC.44.1.103-110.2000 · DOI
  52. Heifets, 1999, Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century, Int J Tuberc Lung Dis, 3, 564
  53. American Thoracic Society, 1997, Rapid diagnostic tests for tuberculosis: what is the appropriate use?, Am J Respir Crit Care Med, 155, 1804, 10.1164/ajrccm.155.5.9154896 · DOI
  54. Behr, 1997, Molecular fingerprinting of Mycobacterium tuberculosis: how can it help the clinician?, Clin Infect Dis, 25, 806, 10.1086/515550 · DOI
  55. Von Pirquet, 1909, Frequency of tuberculosis in childhood, JAMA, 52, 675, 10.1001/jama.1909.25420350001001 · DOI
  56. Seibert, 1941, Tuberculin purified protein derivative: preparation and analyses of a large quantity for standard, AmRevTuberc, 44, 9
  57. Lee, 2002, Evolution and current use of the tuberculin test, Clin Infect Dis, 34, 365, 10.1086/338149 · DOI
  58. Huebner, 1993, The tuberculin skin test, ClinInfect Dis, 17, 968
  59. Mazurek, 2003, Guidelines for using the QuantiFeron-TB test for diagnosing latent Mycobacterium tuberculosis infection, MMWR Morb Mortal Wkly Rep, 52, 15
  60. Kimura, 1999, Comparison between a whole blood interferon-gamma release assay and tuberculin skin testing for the detection of tuberculosis infection among patients at risk for tuberculosis exposure, J Infect Dis, 179, 1297, 10.1086/314707 · DOI
  61. Bellete, 2002, Evaluation of a whole-blood interferon-gamma release assay for the detection of Mycobacterium tuberculosis infection in 2 study populations, Clin Infect Dis, 34, 1449, 10.1086/340397 · DOI
  62. Converse, 1997, Comparison of a tuberculin interferon-gamma assay with the tuberculin skin test in high-risk adults: effect of human immunodeficiency virus infection, J Infect Dis, 176, 144, 10.1086/514016 · DOI
  63. Mazurek, 2001, Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection, JAMA, 286, 1740, 10.1001/jama.286.14.1740 · DOI
  64. Ewer, 2003, Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak, Lancet, 361, 1168, 10.1016/S0140-6736(03)12950-9 · DOI
  65. David, 1970, Probability distribution of drug resistant mutants in unselected populations of Mycobacterium tuberculosis, Appl Microbiol, 20, 810, 10.1128/AEM.20.5.810-814.1970 · DOI
  66. Fox, 1999, Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications, Int J Tuberc Lung Dis, 3, S231
  67. Iseman, 1993, Treatment of multidrug-resistant tuberculosis, NEnglJMed, 329, 784, 10.1056/NEJM199309093291108 · DOI
  68. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America, 2003, Treatment of tuberculosis, Am J Respir Crit Care Med, 167, 603, 10.1164/rccm.167.4.603 · DOI
  69. Joint Tuberculosis Committee of the British Thoracic Society, 1998, Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998, Thorax, 53, 536, 10.1136/thx.53.7.536 · DOI
  70. Hong Kong Chest Service/British Medical Research Council, 1991, Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampicin, and pyrazinamide: results at 30 months, AmRevRespir Dis, 143, 700
  71. Fox, 1993, Compliance of patients and physicians: experience and lessons from tuberculosis I, BMJ, 287, 33, 10.1136/bmj.287.6384.33 · DOI
  72. Weis, 1994, The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis, N Engl J Med, 334, 1179, 10.1056/NEJM199404283301702 · DOI
  73. Chaulk, 1998, Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel, JAMA, 279, 943, 10.1001/jama.279.12.943 · DOI
  74. Kamolratanakul, 1999, Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand, Trans R Soc Trop Med Hyg, 93, 552, 10.1016/S0035-9203(99)90379-6 · DOI
  75. Mitchison, 1979, Basic mechanisms of chemotherapy, Chest, 76, S771, 10.1378/chest.76.6_Supplement.771 · DOI
  76. Frieden, 1999, Directly observed treatment for tuberculosis, Lancet, 353, 146, 10.1016/S0140-6736(05)76181-X · DOI
  77. Pungrassami, 2002, Practice of directly observed treatment (DOT) in southern Thailand: comparison between different types of observers, Int J Tuberc Lung Dis, 6, 389
  78. Frieden, 2002, The slippery slope to sloppy DOTS, Int J Tuberc Lung Dis, 6, 371
  79. Ormerod, 1996, Frequency and type of reactions to antituberculosis drugs: observations in routine treatment, Tuberc Lung Dis, 77, 37, 10.1016/S0962-8479(96)90073-8 · DOI
  80. Girling, 1982, Adverse effects of antituberculosis drugs, Drugs, 23, 56, 10.2165/00003495-198223010-00003 · DOI
  81. British Thoracic Society Research Committee, 1985, Short course chemotherapy for tuberculosis of lymph nodes: a controlled trial, BMJ, 290, 1106, 10.1136/bmj.290.6475.1106 · DOI
  82. MRC Working Party on Tuberculosis of the Spine, 1999, Five-year assessment of controlled trials of short-course chemotherapy regimens of 6, 9 or 18 months' duration for spinal tuberculosis in patients ambulatory from the start or undergoing radical surgery, Int Orthop, 23, 73, 10.1007/s002640050311 · DOI
  83. Balasubramanian, 2000, Management of non-pulmonary forms of tuberculosis: review of TRC studies over two decades, Indian J Pediatr, 67, S34
  84. Yuen, 1997, Prospective randomised study of thrice weekly six-month and nine-month chemotherapy for cervical tuberculous lymphadenopathy, Otolaryngol Head Neck Surg, 116, 189, 10.1016/S0194-5998(97)70323-1 · DOI · Paper page
  85. Donald, 1998, Intensive short course chemotherapy in the management of tuberculosis meningitis, Int J Tuberc Lung Dis, 2, 704
  86. Girgis, 1991, Dexamthasone adjunctive treatment for tuberculous meningitis, Pediatr Infect Dis J, 10, 179, 10.1097/00006454-199103000-00002 · DOI
  87. Schoeman, 1997, Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculosis meningitis, Pediatrics, 99, 226, 10.1542/peds.99.2.226 · DOI
  88. Strang, 1987, Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei, Lancet, 2, 1418, 10.1016/S0140-6736(87)91127-5 · DOI
  89. Strang, 1998, Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei, Lancet, 2, 759
  90. Hakim, 2000, Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients, Heart, 84, 183, 10.1136/heart.84.2.183 · DOI
  91. Lee, 1988, Corticosteroids in the treatment of tuberculous pleurisy: a double-blind, placebo-controlled, randomized study, Chest, 94, 1256, 10.1378/chest.94.6.1256 · DOI
  92. Wyser, 1996, Corticosteroids in the treatment of tuberculosis pleurisy: a double-blind, placebo-controlled, randomised study, Chest, 110, 333, 10.1378/chest.110.2.333 · DOI
  93. Dooley, 1997, Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature, Clin Infect Dis, 25, 872, 10.1086/515543 · DOI
  94. Brost, 1997, The maternal and fetal effects of tuberculosis therapy, Obstet Gynecol Clin North Am, 24, 659, 10.1016/S0889-8545(05)70329-6 · DOI
  95. Valerio, 2003, Long-term tolerance and effectiveness of moxafloxacin therapy for tuberculosis: preliminary results, J Chemother, 15, 66, 10.1179/joc.2003.15.1.66 · DOI
  96. American Academy of Pediatrics, 2001, The transfer of drugs and other chemicals into human milk, Pediatrics, 108, 776, 10.1542/peds.108.3.776 · DOI · Paper page
  97. Malone, 1999, The effect of hemodialysis on cycloserine, ethionamide, paraaminosalicylate, and clofazimine, Chest, 116, 984, 10.1378/chest.116.4.984 · DOI
  98. Malone, 1999, The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol, Am J Respir Crit Care Med, 159, 1580, 10.1164/ajrccm.159.5.9810034 · DOI
  99. Nunn, 1991, Cutaneous hypersensitivity reactions due to thioacetazone in HIV-1 seropositive patients treated for tuberculosis, Lancet, 337, 627, 10.1016/0140-6736(91)92447-A · DOI
  100. Okwera, 1994, Randomised trial of thioacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans, Lancet, 344, 1323, 10.1016/S0140-6736(94)90693-9 · DOI
  101. Elliott, 1995, The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia, Trans R Soc Trop Med Hyg, 89, 78, 10.1016/0035-9203(95)90668-1 · DOI
  102. Harries, 1997, Tuberculosis in Africa: clinical presentation and management, Pharmacol Ther, 73, 1, 10.1016/S0163-7258(96)00115-5 · DOI
  103. Alpert, 1997, A prospective study of tuberculosis and human immunodeficiency virus infection: clinical manifestations and factors associated with survival, Clin Infect Dis, 24, 661, 10.1093/clind/24.4.661 · DOI
  104. Murray, 1999, Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients, Am J Respir Crit Care Med, 159, 733, 10.1164/ajrccm.159.3.9804147 · DOI
  105. Alwood, 1994, Effectiveness of supervised, intermittent therapy for tuberculosis in HIV infected patients, AIDS, 8, 1103, 10.1097/00002030-199408000-00010 · DOI
  106. Driver, 2001, Relapse in persons treated for drug-susceptible tuberculosis in a population with high co-infection with human immunodeficiency virus in New York City, Clin Infect Dis, 33, 1762, 10.1086/323784 · DOI
  107. Elliott, 1995, The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia, J Trop Med Hyg, 98, 9
  108. Mallory, 2000, The impact of HIV infection on recurrence of tuberculosis in South African gold miners, Int J Tuberc Lung Dis, 4, 455
  109. Connolly, 1999, Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa, AIDS, 13, 1543, 10.1097/00002030-199908200-00015 · DOI
  110. Sterling, 1999, Relapse rates after short-course (6 month) treatment of tuberculosis in HIV-infected and uninfected persons, AIDS, 13, 1899, 10.1097/00002030-199910010-00012 · DOI
  111. Sonnenberg, 2001, HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers, Lancet, 358, 1687, 10.1016/S0140-6736(01)06712-5 · DOI
  112. Burman, 1999, Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis, Clin Infect Dis, 28, 419, 10.1086/515174 · DOI
  113. Gonzalez-Montaner, 1994, Rifabutin for the treatment of newly diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin, Tuberc Lung Dis, 75, 341, 10.1016/0962-8479(94)90079-5 · DOI
  114. Schwander, 1995, A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis, Tuberc Lung Dis, 76, 210, 10.1016/S0962-8479(05)80007-3 · DOI
  115. McGregor, 1996, Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis, Am J Respir Crit Care Med, 154, 1462, 10.1164/ajrccm.154.5.8912765 · DOI
  116. Centers for Disease Control and Prevention, 1998, Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations, MMWR Recomm Rep, 47, 1
  117. Burman, 2001, Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy, Am J Respir Crit Care Med, 164, 7, 10.1164/ajrccm.164.1.2101133 · DOI
  118. Munsiff, 2000, Treatment of tuberculosis in patients taking antiretrovirals [erratum AIDS Reader 2000; 10: 206], AIDS Reader, 10, 102
  119. 2002, Notice to readers: acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens, MMWR Morb Mortal Wkly Rep, 51, 214
  120. Vernon, 1999, Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid, Lancet, 353, 1843, 10.1016/S0140-6736(98)11467-8 · DOI
  121. Narita, 1998, Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS, Am J Respir Crit Care Med, 158, 157, 10.1164/ajrccm.158.1.9712001 · DOI · Paper page
  122. Wendel, 2001, Paradoxical worsening of tuberculosis in HIV-infected persons, Chest, 120, 193, 10.1378/chest.120.1.193 · DOI · Paper page
  123. Chambers, 1984, Paradoxical expansion of intracranial tuberculomas during chemotherapy, Lancet, 2, 181, 10.1016/S0140-6736(84)90478-1 · DOI
  124. Wendland, 1999, HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia, AIDS, 13, 1857, 10.1097/00002030-199910010-00007 · DOI
  125. Navas, 2002, Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy, Arch Intern Med, 162, 97, 10.1001/archinte.162.1.97 · DOI
  126. Frieden, 1996, A multi-institutional outbreak of highly drug resistant tuberculosis, JAMA, 276, 1229, 10.1001/jama.1996.03540150031027 · DOI
  127. Dye, 2003, What is the limit to case detection under the DOTS strategy for tuberculosis control?, Tuberculosis, 83, 35, 10.1016/S1472-9792(02)00056-2 · DOI
  128. Dye, 1998, Prospects for worldwide tuberculosis control under the WHO DOTS strategy, Lancet, 352, 1886, 10.1016/S0140-6736(98)03199-7 · DOI
  129. Dye, 2000, Tuberculosis 2000–2010: control, but not elimination, Int J Tuberc Lung Dis, 4, S146
  130. Suárez, 2001, The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru, J Infect Dis, 184, 473, 10.1086/322777 · DOI
  131. Dye, 2000, Evaluating the impact of tuberculosis control: number of deaths prevented by short-course chemotherapy in China, Int J Epidemiol, 29, 558, 10.1093/intjepid/29.3.558 · DOI
  132. Khatri, 2002, Controlling tuberculosis in India, N Engl J Med, 347, 1420, 10.1056/NEJMsa020098 · DOI
  133. Jones, 2000, HIV-associated tuberculosis in the era of highly active antiretroviral therapy, Int J Tuberc Lung Dis, 4, 1026
  134. Badri, 2002, Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study, Lancet, 359, 2059, 10.1016/S0140-6736(02)08904-3 · DOI
  135. Lotte, 1988, Second IUATLD study on complications induced by intradermal BCG-vaccination, Bull Int Union Tuberc Lung Dis, 63, 47
  136. Comstock, 1999, How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?, Int J Tuberc Lung Dis, 3, 847
  137. Jasmer, 2002, Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial, Ann Intern Med, 137, 640, 10.7326/0003-4819-137-8-200210150-00007 · DOI
  138. 2001, Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations–United States, MMWR Morb Mortal Wkly Rep, 50, 733
  139. 2002, Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection, MMWR Morb Mortal Wkly Rep, 51, 998
  140. Wilkinson, 1998, Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo-controlled trials, BMJ, 317, 625, 10.1136/bmj.317.7159.625 · DOI
  141. Johnson, 2001, Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults, AIDS, 15, 2137, 10.1097/00002030-200111090-00009 · DOI
  142. Quigley, 2001, Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults, AIDS, 15, 215, 10.1097/00002030-200101260-00011 · DOI
  143. Murray, 1991, Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries, Lancet, 338, 1305, 10.1016/0140-6736(91)92600-7 · DOI

Cited by

Sorted by citations

Metadata

Authors
Frieden, T. R., Sterling, T. R., Munsiff, S. S., Watt, C. J., & Dye, C.
Venue
The Lancet
Publisher
Elsevier BV
Published
2003-09
Volume
362
Issue
9387
Pages
887-899
ISSN
0140-6736
DOI
10.1016/s0140-6736(03)14333-4
Cited by
689
References
3
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review